Sphingosine

• 

  Subject Areas on Research

  • A blood spot method for detecting fumonisin-induced changes in putative sphingolipid biomarkers in LM/Bc mice and humans. 
  • A cross-sectional study of human serum sphingolipids, diet and physiologic parameters. 
  • A high-performance liquid chromatographic method to measure sphingosine 1-phosphate and related compounds from sphingosine kinase assays and other biological samples. 
  • A rapid radioassay for sphingosine kinase. 
  • Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase. Formation of N-palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP1, and a new category of ceramide synthase inhibitor. 
  • Alteration of tissue and serum sphinganine to sphingosine ratio: an early biomarker of exposure to fumonisin-containing feeds in pigs. 
  • Analysis of sphingoid bases and sphingoid base 1-phosphates by high-performance liquid chromatography. 
  • Bioactive lysophospholipids: role in regulation of aqueous humor outflow and intraocular pressure in the context of pathobiology and therapy of glaucoma. 
  • Biosynthesis of long-chain (sphingoid) bases from serine by LM cells. Evidence for introduction of the 4-trans-double bond after de novo biosynthesis of N-acylsphinganine(s). 
  • CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. 
  • Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. 
  • Characterization of cell-cycle arrest by fumonisin B1 in CV-1 cells. 
  • Characterization of ceramide synthesis. A dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide. 
  • Characterization of new gangliosides of the lactotetraose series in murine xenografts of a human glioma cell line. 
  • Chronic toxicity of fumonisins from Fusarium moniliforme culture material (M-1325) to mink. 
  • Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. 
  • Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate. 
  • Dietary fumonisin B1 induces disruption of sphingolipid metabolism in Sprague-Dawley rats: a new mechanism of nephrotoxicity. 
  • Differences in the long chain (sphingoid) base composition of sphingomyelin from rats bearing Morris hepatoma 7777. 
  • Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. 
  • Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. 
  • Dupuytren's fibroblast contractility by sphingosine-1-phosphate is mediated through non-muscle myosin II. 
  • Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. 
  • Effects of sphingosine-1-phosphate and ceramide-1-phosphate on rat intestinal smooth muscle cells: implications for postoperative ileus. 
  • Enzymes of ceramide biosynthesis. 
  • Enzymology of long-chain base synthesis by liver: characterization of serine palmitoyltransferase in rat liver microsomes. 
  • Evidence for fumonisin inhibition of ceramide synthase in humans consuming maize-based foods and living in high exposure communities in Guatemala. 
  • FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. 
  • Fingolimod therapy and macular hemorrhage. 
  • Fingolimod-associated macular edema: incidence, detection, and management. 
  • Free sphingosine formation from endogenous substrates by a liver plasma membrane system with a divalent cation dependence and a neutral pH optimum. 
  • Fumonisin B1 alters sphingolipid metabolism and disrupts the barrier function of endothelial cells in culture. 
  • Fumonisin B1 consumption by rats causes reversible, dose-dependent increases in urinary sphinganine and sphingosine. 
  • Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. 
  • Fumonisin inhibition of de novo sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK1 cells. 
  • Fumonisins and fumonisin analogs as inhibitors of ceramide synthase and inducers of apoptosis. 
  • Hippocampal programmed cell death after status epilepticus: evidence for NMDA-receptor and ceramide-mediated mechanisms. 
  • Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. 
  • Identification, partial purification, and characterization of a novel phospholipid-dependent and fatty acid-activated protein kinase from human platelets. 
  • In vitro toxicology of fumonisins and the mechanistic implications. 
  • Increases in serum sphingosine and sphinganine and decreases in complex sphingolipids in ponies given feed containing fumonisins, mycotoxins produced by Fusarium moniliforme. 
  • Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. 
  • Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. 
  • Long-chain (sphingoid) bases inhibit multistage carcinogenesis in mouse C3H/10T1/2 cells treated with radiation and phorbol 12-myristate 13-acetate. 
  • Metabolomic profiling of sphingolipids in human glioma cell lines by liquid chromatography tandem mass spectrometry. 
  • Modulation of the free sphingosine levels in human neutrophils by phorbol esters and other factors. 
  • N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. 
  • Necroptosis of infiltrated macrophages drives Yersinia pestis dispersal within buboes. 
  • P2X7 receptor agonists pre- and postcondition the heart against ischemia-reperfusion injury by opening pannexin-1/P2X₇ channels. 
  • Pannexin-I/P2X 7 purinergic receptor channels mediate the release of cardioprotectants induced by ischemic pre- and postconditioning. 
  • Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes. 
  • Phytosphingosine as a specific inhibitor of growth and nutrient import in Saccharomyces cerevisiae. 
  • Quantitation of free sphingosine in liver by high-performance liquid chromatography. 
  • Regulation of membrane release in apoptosis. 
  • Regulation of phosphatidate phosphatase activity from the yeast Saccharomyces cerevisiae by sphingoid bases. 
  • Role of lysophospholipid growth factors in the modulation of aqueous humor outflow facility. 
  • Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. 
  • S1P-Dependent trafficking of intracellular yersinia pestis through lymph nodes establishes Buboes and systemic infection. 
  • S1P₂ receptor regulation of sphingosine-1-phosphate effects on conventional outflow physiology. 
  • SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. 
  • Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. 
  • Should we B-leavin' now? 
  • Sphingoid bases and de novo ceramide synthesis: enzymes involved, pharmacology and mechanisms of action. 
  • Sphingolipid biosynthesis by rat liver cells: effects of serine, fatty acids and lipoproteins. 
  • Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins. 
  • Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. 
  • Sphingolipids as biomarkers of fumonisin exposure and risk of esophageal squamous cell carcinoma in china. 
  • Sphingolipids signal heat stress-induced ubiquitin-dependent proteolysis. 
  • Sphingosine can pre- and post-condition heart and utilizes a different mechanism from sphingosine 1-phosphate. 
  • Sphingosine inhibits monocyte tissue factor-initiated coagulation by altering factor VII binding. 
  • Sphingosine protects aging hearts from ischemia/reperfusion injury: Superiority to sphingosine 1-phosphate and ischemic pre- and post-conditioning. 
  • Sphingosine-1-phosphate effects on the inner wall of Schlemm's canal and outflow facility in perfused human eyes. 
  • Sphingosine-1-phosphate enhancement of cortical actomyosin organization in cultured human Schlemm's canal endothelial cell monolayers. 
  • Sphingosine-1-phosphate phosphohydrolase regulates endoplasmic reticulum-to-golgi trafficking of ceramide. 
  • Sphingosine-1-phosphate signaling regulates lamellipodia localization of cortactin complexes in endothelial cells. 
  • Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis. 
  • Steroidogenic factor-1 is a sphingolipid binding protein. 
  • Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. 
  • Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. 
• 

  Keywords of People

  • Gunn, Michael Dee, Professor of Medicine, Immunology